Approach

Summary

Licensing status

Publication and contact information

Drug platforms

Engineered HPV particles that encapsulate viral genes for intravaginal vaccination against infection

Mouse studies suggest intravaginal immunization using engineered HPV particles could help protect against mucosal pathogens. In mice, intravaginal vaccination with different engineered HPV particles that encapsulate a proof-of-concept antigen led to strong, durable antigen-specific CD8+ T cell responses in the cervicovaginal mucus, whereas intramuscular or intranasal vaccine delivery methods led to dampened antigen-specific CD8+ T cell responses. Mice that received the intravaginal vaccine were protected against challenge with a virus expressing the proof-of-concept antigen two months after immunization boost. Next steps include testing the engineered HPV particles as prophylactic vaccines for herpes simplex virus (HSV) and HPV infection.

SciBX 5(47); doi:10.1038/scibx.2012.1244
Published online Dec. 6, 2012

Patent application filed; vectors and use in preventing cancer and sexually transmitted infections available for licensing

Çuburu, N. et al. J. Clin. Invest.; published online Nov. 12, 2012;
doi:10.1172/JCI63287
Contact: John T. Schiller, National Cancer Institute, Bethesda, Md.
e-mail:

schillej@dc37a.nci.nih.gov